Edgewise Therapeutics, Inc.

EWTX Healthcare Biotechnology

In the quarter to June 2026, EPS fell 55.9% and free cash flow fell 30.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

37.19 1.01 −2.64%
Market cap
$4.2B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
— 29.86 26.97 21.53 19.50 19.93 19.85
Net Debt/EBITDA
— 7.59 6.54 4.91 2.61 2.78 2.69
Debt/Equity
— 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— (14.21%) (35.53%) (21.78%) (30.10%) (34.40%) (34.19%)
ROA
— (26.11%) (20.56%) (20.74%) (28.33%) (32.37%) (32.29%)
ROIC
— 0.00% 0.00% 0.00% (16,355.41%) 0.00% 0.00%
Return on Tangible Assets
— (13.61%) (15.62%) (19.38%) (31.24%) (29.02%) (32.03%)
Free Cash Flow per Share
— (20.08) (0.91) (1.09) (1.53) (1.19) (1.40)
Book value per Share
— 171.58 7.31 6.47 5.00 4.97 5.07
Free Cash Flow
— (14.84) (34.17) (58.18) (97.69) (110.34) (144.07)
Other line items

Show all line items

Columns are period end dates